{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-017226","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2026-05-15T12:30:15+00:00","discovered_at":"2026-05-15T12:35:00.324605+00:00","generated_at":"2026-05-15T12:36:23.982752+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Moleculin Q1: Cash $10.3M; MIRACLE trial 40% CRc; 45 subjects enrolled","bullets":["Cash and equivalents $10.3M as of March 31, 2026; R&D expense $5.4M (up $2.0M YoY) on MIRACLE trial costs.","MIRACLE Phase 2B/3 trial: first 45 subjects enrolled; blinded composite complete remission (CRc) rate of 40%.","First interim unblinding expected June 2026; 90th subject recruitment targeted for Q3 2026.","Completed Q1 2026 financings with ~$8.3M gross proceeds; runway extended into Q3 2026.","Expect to start pancreatic cancer trial in 2H 2026; aiming for rolling NDA submission for R/R AML in 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-017226","json":"https://secwatch.observer/filing/0001437749-26-017226.json","markdown":"https://secwatch.observer/filing/0001437749-26-017226.md","text":"https://secwatch.observer/filing/0001437749-26-017226.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926017226/0001437749-26-017226-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926017226/mbrx20260514_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T12:36:23.982752+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"796aa21455c8caeb2c14ae6232d400d72a3373ab","claim":"Moleculin Biotech, Inc. reported financial results for first quarter ended March 31, 2026.","evidence_excerpt":"On May 15, 2026, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026 and recent operational highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1659617/000143774926017226/0001437749-26-017226-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}